An interventional study of Gixam System and FIT in CRC Screening and Microbiome, sponsored by Jubaan Ltd.. Recruiting at 8 sites in United States. Open to participants aged 45 Years to 84 Years. Per ClinicalTrials.gov, last updated 2026-09-21.
Sponsored by Jubaan Ltd. · Not applicable, Interventional, and Screening
The goal of this clinical trial is to learn if the Gixam device effectively identifies persons with pre-cancer or cancer in the colon and rectum in adults aged 45-84 that are of average risk to develop colorectal cancer and have received a negative result on a Fecal Immunochemical Test (FIT). The main questions it aims to answer are:
Gixam test result will be compared to the findings of a standard of care screening colonoscopy.
Study participants will:
Jubaan Ltd. is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participant has a diagnosis or medical / family history of any of the following conditions, including:
All enrolled participants will undergo the same intervention: Gixam test, FIT, and screening colonoscopy
Device: Gixam System · Diagnostic Test: FIT · Procedure: Standard of care screening colonoscopy
All participant will undergo the Gixam test per device instructions for use
FIT kit will be handed out to the study participant, who will later sample stool at home and mail the specimen to a reference laboratory for analysis.
All participants will undergo a standard of care screening colonoscopy which serves as the gold truth in this study
Primary Safety Endpoint
Number of device-related adverse events and serious adverse events.
Time frame: From enrollment to the end of study at 30 days after
Primary Efficacy Endpoints
Sensitivity and specificity of Gixam in participants with a negative FIT result.
Time frame: Through study completion, an average of 30 days
Confirmatory Secondary Efficacy Endpoints
Standalone sensitivity and specificity of Gixam in general average risk population.
Time frame: Through study completion, an average of 30 days
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jubaan Ltd.